1
|
Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, Cortal M, Gómez-Ferrería M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domènech C, Alfón J, Gascón P. A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. Eur J Cancer 2021; 146:87-94. [PMID: 33588149 DOI: 10.1016/j.ejca.2020.12.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 12/17/2020] [Accepted: 12/18/2020] [Indexed: 01/13/2023]
Abstract
BACKGROUND ABTL0812 is an autophagy inducer that promotes cancer cell death by activation of cytotoxic autophagy selectively in tumour cells. ABTL0812 induces endoplasmic reticulum stress and blocks the Akt-mTOR axis; both actions converge to activate a robust and sustained autophagy leading to cancer cell death. Preclinical data supported the initiation of clinical trials in patients with cancer. PATIENTS AND METHODS This first-in-human trial consisted of an escalation phase (3 + 3 design), followed by an expansion phase, to assess safety and tolerability of ABTL0812. Secondary objectives were determining the recommended phase II dose (RP2D), clinical antitumour activity, pharmacokinetics (PK) and pharmacodynamics (PD). RESULTS A total of 29 patients were enrolled and treated; fifteen patients were treated in four escalation dosing cohorts (ranging from 500 mg once a day to 2000 mg twice a day) and fourteen in the expansion phase (dosed with 1300 mg three times a day). No maximum tolerated dose was attained, and RP2D was determined by PK/PD modelling. Most drug-related adverse events were gastrointestinal grade I-II. Correlation between drug levels and pAkt/Akt ratio was found. Two cases of long-term (>1 year) stable disease were observed. CONCLUSIONS ABTL0812 is safe and has an acceptable tolerability profile, allowing a long-term oral dosing. RP2D of 1300 mg three times a day was determined according to PK/PD modelling, and preliminary antitumour efficacy was observed. CLINICAL TRIAL REGISTRATION NUMBER NCT02201823.
Collapse
Affiliation(s)
- Laura Vidal
- IntherUnit, Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain
| | - Ivan Victoria
- IntherUnit, Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain
| | - Lydia Gaba
- Department of Medical Oncology, Hospital Clinic, Barcelona Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain
| | - Marta Gil Martín
- Medical Oncology, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
| | - Mercè Brunet
- Biomedical Diagnostic Center (CDB), Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain
| | - Helena Colom
- Department of Pharmacy, Pharmaceutical Technology and Physical-Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Catalonia, Spain
| | - Marc Cortal
- Ability Pharmaceuticals, SL, Cerdanyola del Vallès, Barcelona, Catalonia, Spain
| | | | - Marc Yeste-Velasco
- Ability Pharmaceuticals, SL, Cerdanyola del Vallès, Barcelona, Catalonia, Spain
| | - Antonio Perez
- Ability Pharmaceuticals, SL, Cerdanyola del Vallès, Barcelona, Catalonia, Spain
| | - Jordi Rodon
- Early Clinical Drug Development Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Catalonia, Spain; Department of Thoracic/Head & Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | - Davendra P S Sohal
- Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH, USA
| | - José Miguel Lizcano
- Departament of Biochemistry and Institute of Neuroscience, School of Medicine, Autonomous University of Barcelona, Bellaterra, Barcelona, Catalonia, Spain
| | - Carles Domènech
- Ability Pharmaceuticals, SL, Cerdanyola del Vallès, Barcelona, Catalonia, Spain
| | - José Alfón
- Ability Pharmaceuticals, SL, Cerdanyola del Vallès, Barcelona, Catalonia, Spain.
| | - Pere Gascón
- IntherUnit, Hospital Clínic i Provincial de Barcelona, Barcelona, Catalonia, Spain
| |
Collapse
|
2
|
Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol 2019; 29:2121-2128. [PMID: 30165419 DOI: 10.1093/annonc/mdy335] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Background We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types. Patients and methods RNASeqv2 data from 10 078 tumor samples representing 34 different cancer types was analyzed from TCGA. Eighteen immune-related gene signatures and 547 immune-related genes, including PD1, were explored. Correlations between each gene/signature and ORRs reported in the literature following anti-PD1 monotherapy were calculated. To translate the in silico findings to the clinical setting, we analyzed the expression of PD1 mRNA using the nCounter platform in 773 formalin-fixed paraffin embedded (FFPE) tumor samples across 17 cancer types. To test the direct relationship between PD1 mRNA, PDL1 immunohistochemistry (IHC), stromal tumor-infiltrating lymphocytes (sTILs) and ORR, we evaluated an independent FFPE-based dataset of 117 patients with advanced disease treated with anti-PD1 monotherapy. Results In pan-cancer TCGA, PD1 mRNA expression was found strongly correlated (r > 0.80) with CD8 T-cell genes and signatures and the proportion of PD1 mRNA-high tumors (80th percentile) within a given cancer type was variable (0%-84%). Strikingly, the PD1-high proportions across cancer types were found strongly correlated (r = 0.91) with the ORR following anti-PD1 monotherapy reported in the literature. Lower correlations were found with other immune-related genes/signatures, including PDL1. Using the same population-based cutoff (80th percentile), similar proportions of PD1-high disease in a given cancer type were identified in our in-house 773 tumor dataset as compared with TCGA. Finally, the pre-established PD1 mRNA FFPE-based cutoff was found significantly associated with anti-PD1 response in 117 patients with advanced disease (PD1-high 51.5%, PD1-intermediate 26.6% and PD1-low 15.0%; odds ratio between PD1-high and PD1-intermediate/low = 8.31; P < 0.001). In this same dataset, PDL1 tumor expression by IHC or percentage of sTILs was not found associated with response. Conclusions Our study provides a clinically applicable assay that links PD1 mRNA abundance, activated CD8 T-cells and anti-PD1 efficacy.
Collapse
Affiliation(s)
- L Paré
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - T Pascual
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - E Seguí
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - C Teixidó
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Pathology Service, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Gonzalez-Cao
- Quironsalud Group, Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Barcelona, Spain
| | - P Galván
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - A Rodríguez
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - B González
- Pathology Service, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Cuatrecasas
- Pathology Service, Hospital Clínic of Barcelona, Barcelona, Spain
| | - E Pineda
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - A Torné
- Gynecology Service, Hospital Clínic of Barcelona, Barcelona, Spain
| | - G Crespo
- Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain
| | - S Martin-Algarra
- Department of Medical Oncology, Clínica Universitaria de Navarra, Pamplona, Spain
| | - E Pérez-Ruiz
- Department of Medical Oncology, Hospital Costa del Sol REDISSEC, Marbella, Spain
| | - Ò Reig
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Viladot
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - C Font
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - B Adamo
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Vidal
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - L Gaba
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Muñoz
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - I Victoria
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - G Ruiz
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - N Viñolas
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - B Mellado
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - J Maurel
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - J Garcia-Corbacho
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - M Á Molina-Vila
- Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain
| | - M Juan
- Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - J M Llovet
- BCLC Group, Translational Research Lab in Hepatic Oncology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Universitat de Barcelona; Barcelona, Spain; Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
| | - N Reguart
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - A Arance
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain
| | - A Prat
- Translational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.
| |
Collapse
|
3
|
Jimenez N, Reig O, Montalbo R, Milà-Guasch M, Nadal-Dieste L, Victoria I, Font A, Rodriguez-Vida A, Carles J, Suárez C, Domenech M, Sala-González N, Fernández P, Prat A, Marín-Aguilera M, Mellado B. Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
De Aledo-Castillo JG, Victoria I, Arcocha A, Reguart N, Porto RM, Puig-Butillé J. Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.1196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Buxó E, Sosa A, Reig O, Victoria I, Caballero M, Grau JJ, Garcia-Morillo M. Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study. Ann Otol Rhinol Laryngol 2018; 127:456-462. [PMID: 29852745 DOI: 10.1177/0003489418778066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES In the EXTREME trial, a combination of cisplatin or carboplatin plus 5-fluorouracil (5-FU) and cetuximab was superior to cisplatin/carboplatin plus 5-FU for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). With the aim of improving fluoropyrimidine-related tolerance without decreasing its efficacy, the safety and efficacy of carboplatin plus the oral fluoropyrimidine tegafur and cetuximab were investigated. METHODS A retrospective analysis of 104 patients with recurrent or metastatic HNSCC was conducted. Patients were treated with carboplatin (area under the curve: 5 mg/mL/min) on day 1, oral tegafur (250 mg/m2 twice daily) for 21 consecutive days, and cetuximab (400 mg/m2 as an initial 2-hour intravenous infusion, then 250 mg/m2 as a 1-hour weekly infusion for 3 weeks) for ≤6 cycles. Patients who responded to the therapy then received weekly cetuximab maintenance therapy. RESULTS Treatment was well tolerated with a high level of compliance (relative dose intensity: 96%, 88%, and 81% for carboplatin, tegafur, and cetuximab, respectively). Grade 3-4 adverse events (AEs) were observed in 38% of patients (skin reactions in 17% of patients, anemia 4%, and neutropenia 3%). Grade 1-2 AEs included skin reactions (52% of patients), hypomagnesemia (20%), asthenia (19%), and anemia (13%). No venous thrombosis related to chemotherapy perfusion was observed. Over a median follow-up of 21 months, the median overall and progression-free survival were 11 and 6 months, respectively, and the overall response rate was 35%. CONCLUSIONS Carboplatin plus oral tegafur and cetuximab is a safe, well-tolerated first-line therapy for recurrent or metastatic HNSCC.
Collapse
Affiliation(s)
- Elvira Buxó
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Aaron Sosa
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Oscar Reig
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ivan Victoria
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Miguel Caballero
- 2 Otorhinolaryngology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,3 AMiQ-Otorhinolaryngology, Hospital Dexeus, Barcelona, Spain
| | - Juan José Grau
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Marcial Garcia-Morillo
- 1 Medical Oncology Departments, Hospital Clinic of Barcelona, University of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
6
|
Xipell M, Victoria I, Hoffmann V, Villarreal J, García-Herrera A, Reig O, Rodas L, Blasco M, Poch E, Mellado B, Quintana LF. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology 2018; 7:e1445952. [PMID: 29900063 DOI: 10.1080/2162402x.2018.1445952] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 02/20/2018] [Accepted: 02/23/2018] [Indexed: 12/14/2022] Open
Abstract
Direct stimulation of the antitumor activity of immune system through checkpoint inhibitors (ICIs) has demonstrated efficacy in the treatment of different cancer types. The activity of these antibodies takes place in the immunological synapse blocking the binding of the negative immunoregulatory proteins, thus leading to the finalization of the immune response. Despite having a favorable toxicity profile, its mechanism of action impedes the negative regulation of the immune activity which can potentially favor autoimmune attacks to normal tissues. Renal toxicity has been described in several ICI but not with atezolizumab, an IgG1 monoclonal antibody targeting PD-L1 (programmed death ligand 1), approved by FDA as a second-line therapy for advanced urothelial carcinoma. Here we present a patient with a single kidney and metastatic renal cell carcinoma treated with atezolizumab and bevacizumab combination, with biopsy-proven acute interstitial nephritis, who had a complete resolution of renal dysfunction after steroid therapy.
Collapse
Affiliation(s)
- M Xipell
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - I Victoria
- Oncology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - V Hoffmann
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - J Villarreal
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - A García-Herrera
- Pathology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - O Reig
- Oncology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - L Rodas
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - M Blasco
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - E Poch
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - B Mellado
- Oncology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - L F Quintana
- Nephrology and Renal Transplantation Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Vilariño N, Puig-Butille J, Reyes R, Victoria I, Arcocha A, Jares P, Viñolas N, De Aledo JG, Molina R, Teixido C, Prat A, Reguart N. P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Marín-Aguilera M, Reig O, Font A, Rodríguez-Vida A, Suárez C, Domenech M, Jiménez N, Victoria I, López S, Milà-Guasch M, Felip E, Etxaniz O, Carles J, Racca F, Sala-González N, González del Alba A, Fernández P, Prat A, Mellado B. Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, Casanova-Molla J, Graus F. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve 2017; 56:E162-E167. [DOI: 10.1002/mus.25672] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 03/23/2017] [Accepted: 04/17/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Maria Sepúlveda
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
- Neuroimmunology Program; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - Eugenia Martinez-Hernandez
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
- Neuroimmunology Program; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - Lydia Gaba
- Medical Oncology Department; Hospital Clínic, University of Barcelona; Barcelona Spain
| | - Ivan Victoria
- Medical Oncology Department; Hospital Clínic, University of Barcelona; Barcelona Spain
| | - Nuria Sola-Valls
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
- Neuroimmunology Program; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - Neus Falgàs
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
| | - Jordi Casanova-Molla
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
| | - Francesc Graus
- Department of Neurology; Hospital Clínic, University of Barcelona; Barcelona Spain
- Neuroimmunology Program; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| |
Collapse
|
10
|
Erfan G, Puig S, Carrera C, Arance A, Gaba L, Victoria I, Garcia-Herrera A, Alos L, Malvehy J. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Acta Derm Venereol 2017; 97:258-260. [PMID: 27353949 DOI: 10.2340/00015555-2488] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carcinoma, Basal Cell/chemically induced
- Carcinoma, Basal Cell/prevention & control
- Carcinoma, Squamous Cell/chemically induced
- Carcinoma, Squamous Cell/prevention & control
- Drug Eruptions/etiology
- Drug Eruptions/prevention & control
- Female
- Humans
- Imidazoles/administration & dosage
- Imidazoles/adverse effects
- Indoles/administration & dosage
- Indoles/adverse effects
- Keratoacanthoma/chemically induced
- Keratoacanthoma/prevention & control
- Keratoderma, Palmoplantar/chemically induced
- Keratoderma, Palmoplantar/prevention & control
- Keratosis, Actinic/chemically induced
- Keratosis, Actinic/prevention & control
- Keratosis, Seborrheic/chemically induced
- Keratosis, Seborrheic/prevention & control
- Male
- Melanoma/drug therapy
- Middle Aged
- Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors
- Oximes/administration & dosage
- Oximes/adverse effects
- Photosensitivity Disorders/chemically induced
- Photosensitivity Disorders/prevention & control
- Proto-Oncogene Proteins B-raf/antagonists & inhibitors
- Pyridones/administration & dosage
- Pyrimidinones/administration & dosage
- Skin Neoplasms/drug therapy
- Sulfonamides/administration & dosage
- Sulfonamides/adverse effects
- Vemurafenib
Collapse
Affiliation(s)
- Gamze Erfan
- Dermatology Department, Melanoma Unit, Hospital Clinic and IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Alfon J, Vidal L, Gaba L, Victoria I, Gil M, Laquente B, Brunet M, Colom H, Ramis J, Perez-Montoyo H, Cortal M, Gomez-Ferreria M, Muñoz P, Erazo T, Lizcano J, Domenech C, Gascon P. Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M, Pineda E, Gascon P, Prat A, Arance A. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clin Transl Oncol 2016; 19:119-124. [PMID: 27147251 DOI: 10.1007/s12094-016-1514-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 04/18/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE Immunotherapy (IT) agents and BRAF inhibitors (BRAFi) are effective treatments for patients with advanced BRAF-mutant melanoma although the optimal sequence remains to be elucidated. The aim of this study was to compare the outcomes of two different cohorts of patients treated with BRAFi first, then IT or the reverse sequence. PATIENTS AND METHODS This is a retrospective study on two groups of patients: a cohort was treated first with BRAFi followed by immunotherapy (BRAFi-IT) and the other cohort with the reverse sequence (IT-BRAFi). Baseline characteristics and clinical outcomes were compared between the two cohorts. RESULTS A total of 25 patients were included in the study. Sixteen patients were given BRAFi-IT sequence and nine received IT-BRAFi sequence. No differences were observed in the characteristics of patients prior to each treatment between cohorts. Objective response rate (ORR) achieved by BRAFi were not different among groups. ORR achieved by IT was higher when administered after BRAFi (43.8 vs 0 %). Survival rates at 1-2 years were similar in both cohorts and median overall survival was not different for BRAFi-IT and IT-BRAFi (log rank test p = 0.97). CONCLUSIONS No differences were observed in OS between the two cohorts. These results support the indistinct use of IT or BRAFi as initial treatment in patients with metastatic BRAF-mutant melanoma, although higher rate of response to IT was observed when administered after BRAFi. Prospective randomized clinical trials are needed on this issue.
Collapse
Affiliation(s)
- F Aya
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. .,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - A Fernandez-Martinez
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - L Gaba
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - I Victoria
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - M Tosca
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - E Pineda
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - P Gascon
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - A Prat
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - A Arance
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
13
|
Aya F, Gaba L, Victoria I, Fernandez-Martinez A, Ruiz-Esquide V, Pineda E, Tosca M, Viladot M, Pereira V, Malvehy J, Prat A, Arance A. Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open 2016; 1:e000032. [PMID: 27843587 PMCID: PMC5070207 DOI: 10.1136/esmoopen-2015-000032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 01/14/2016] [Indexed: 01/18/2023] Open
Abstract
Immune checkpoint inhibitors, such as ipilimumab (an anti-CTLA4 antibody), have become a commonly used therapy in cancer. To date, safety data of patients with underlying autoimmune disease is limited. We present a case of a patient with rheumatoid arthritis who was diagnosed of a BRAF-mutant metastatic melanoma. The patient was treated with ipilimumab and presented with high-grade colitis requiring immunosuppressors. Despite of the immune-related adverse event, no exacerbation of the rheumatoid arthritis was observed and the patient achieved a complete response. This case report contributes to the scarce literature on the use of immune checkpoint inhibitors in patients with an underlying autoimmune condition.
Collapse
Affiliation(s)
- Francisco Aya
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Lydia Gaba
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ivan Victoria
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Aranzazu Fernandez-Martinez
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Virginia Ruiz-Esquide
- Department of Rheumatology, Hospital Clinic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Estela Pineda
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Monica Tosca
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Margarita Viladot
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Veronica Pereira
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Josep Malvehy
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Aleix Prat
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ana Arance
- Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
14
|
Riu G, Gaba L, Victoria I, Molas G, do Pazo F, Gómez B, Creus N, Vidal L. Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. Eur J Cancer Care (Engl) 2016; 27. [PMID: 26786594 DOI: 10.1111/ecc.12447] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2015] [Indexed: 01/20/2023]
Abstract
A pharmaceutical care programme was implemented at our hospital in early 2013. The main objectives were to analyse and describe the pharmaceutical interventions made, to calculate adherence, interventions and to evaluate patient satisfaction with the care programme. We performed a single-centre descriptive and prospective intervention in cancer patients who received oral chemotherapy as part of a clinical trial in 2013. Eighty-three patients were included. Median age was 58 years (range, 31-80) and 42 patients (50.6%) were men. We recorded 23 interventions, 13 of which were associated with drug interactions. The mean percentage of adherence was 98.9%. The interview with the pharmacist was considered to be very important by 84.6% of the respondents. A total of 92.3% said that they would like to speak to the pharmacist at subsequent visits. The doubts detected during the visits enable us to conclude that the information patients receive with respect to their study medication is usually incomplete. An integrated pharmaceutical care programme for cancer patients participating in clinical trials with oral cytostatic drugs was successful in terms of adherence and patient satisfaction and makes it possible to guarantee the safety and effectiveness of treatment on an individual basis.
Collapse
Affiliation(s)
- G Riu
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Gaba
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - I Victoria
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - G Molas
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - F do Pazo
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - B Gómez
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - N Creus
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Vidal
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| |
Collapse
|
15
|
Vidal L, Gaba L, Victoria I, Gil-Martin M, Laquente B, Cortal M, Brunet M, Paredes P, Gomez-Ferreria M, Alfon J, Domenech C, Gascon P. Abstract LB-C18: First-in-Human Clinical Trial of ABTL0812, a Compound that Inhibits PI3K/Akt/mTOR Pathway by Upregulating TRIB3, in Patients with Advanced Solid Tumors. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-lb-c18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: ABTL0812 is a first-in-class antitumor drug whose mechanism of action relies on the inhibition of PI3K/Akt/mTOR (PAM) pathway by upregulation of TRIB3 levels, an endogenous inhibitor of Akt activity that prevents Akt phosphorylation. Preclinical studies showed good efficacy of ABTL0812 in xenograft models with high safety margin. Here we describe the First-in-Human (FiH) Phase I/Ib clinical trial of ABTL0812 in patients with advanced solid tumors (NCT02201823).
Methods: ABTL0812 was dosed daily, by the oral route, in 28-day cycles. The study included a 4-cohort dose escalation, in a 3+3 dose escalating design, followed by an expansion cohort. The trial objectives were to determine safety and tolerability, to evaluate signs of efficacy, to determine drug pharmacokinetics (PK) in plasma and to analyze inhibition of Akt phosphorylation in platelets by MSD® as pharmacodynamic (PD) biomarker. Pretreatment tumor biopsies were analyzed by next generation sequencing to identify mutations in a panel of 50 cancer-related genes.
Results: Fifteen patients were recruited in the escalation part and 14 patients in the expansion cohort (February 2014 to May 2015). No dose-limiting-toxicities were detected and the recommended Phase II was 1300 mg tid based on PK/PD modeling. The median number of previous chemotherapy lines was 2 (range 0-11). The profile of ABTL0812 grade 1-2 related adverse events (AEs) included asthenia, nausea/vomiting and throat burning (34%, 31% and 24% of patients, respectively). Only one case of grade 3-4 AE (elevated hepatic enzymes) appeared. ABTL0812 half-life was short (3-5 h), which supported the increase in the administration schedule from once to twice and finally to three times a day. Biomarker analysis showed inhibition of Akt phosphorylation with increasing doses, with average 90% inhibition in the expansion cohort; furthermore it correlated with C-trough plasma levels. Five patients had stable disease (SD) for at least 16 weeks: 1 endometrial cancer (62 weeks), 1 cholangiocarcinoma (35 weeks, ongoing on Sep 15th, 2015), 2 colorectal cancer (28 and 22 weeks) and 1 lung adenocarcinoma (16 weeks). The median time to progression in the expansion cohort was 11 weeks (range 1-≥35 weeks). Interestingly, the tumor biopsy from the patient with endometrial cancer had activating mutations in Akt1 (E17K) and PIK3CA (R88Q). The tumor from the patient with colorectal cancer (28 weeks SD) showed deleterious mutations in TP53 (R248W) and APC (Q1469Ter). None of these samples included major mutations in Ras.
Conclusions: ABTL0812 is a PAM pathway inhibitor acting by a novel mechanism of action that involves upregulation of TRIB3 levels. The FiH Phase I/Ib study in patients with advanced solid tumors showed excellent tolerability and safety profile and demonstrated dose-dependent inhibition of Akt phosphorylation. ABTL0812 treatment induced several long term disease stabilizations (5/29), being the best responder a patient with endometrial cancer (68 weeks) with activating mutations in Akt1 and PIK3CA. Based on these data, a Phase II clinical trial in patients with endometrial cancer is planned.
Citation Format: Laura Vidal, Lydia Gaba, Ivan Victoria, Marta Gil-Martin, Berta Laquente, Marc Cortal, Merce Brunet, Pilar Paredes, Mariana Gomez-Ferreria, Jose Alfon, Carles Domenech, Pedro Gascon. First-in-Human Clinical Trial of ABTL0812, a Compound that Inhibits PI3K/Akt/mTOR Pathway by Upregulating TRIB3, in Patients with Advanced Solid Tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr LB-C18.
Collapse
Affiliation(s)
| | | | | | | | | | - Marc Cortal
- 3Ability Pharmaceuticals SL, Bellaterra, Spain
| | | | | | | | - Jose Alfon
- 3Ability Pharmaceuticals SL, Bellaterra, Spain
| | | | | |
Collapse
|
16
|
Moreno FA, Fernandez-Martinez A, Gaba L, Victoria I, Fernandez AA. Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv514.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Riu G, Victoria I, Garcia LG, Molas G, Pazo FD, Creus N, Gomez B, Vidal L. Implementation of a Pharmaceutical Care Programme for Patients Treated with Investigational Oral Drugs in a Clinical Trials Unit. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Riu G, Gaba L, Victoria I, Molas G, Do Pazo F, Creus N, Vidal L. PS-081 Implementation of a pharmaceutical care programme for patients treated with investigational oral drugs in a clinical trials unit. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
19
|
Grau J, Caballero M, Vilalta A, Victoria I, Reig O, Gascon P, Carrera C, Malvehy J. Electrochemotherapy (ECT) with Bleomycin as a Palliative Treatment of Regional Relapse in Head and Neck Cancer (H&NC) Patients (PTS). a Pilot Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33602-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
20
|
Torras OR, Sebastia M, Victoria I, Paño B, Campayo M, Nicolau C, Mellado B. Preliminary Results of Early Assessment of Response with Perfusion-CT in Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33426-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
Reig O, Font C, Victoria I, Villalta J, Farrús B, Reverter J, Tàssies D, Tuca A, Gascon P. Thrombotic superior vena cava syndrome in cancer patients: data from a single center cohort of 340 consecutive patients. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70104-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Ortega V, Gaba L, Font C, Reig O, Victoria I, Visa L, Pineda E, Oleaga L, Gascon P. Central nervous system venous thrombosis in cancer: Frequency and clinical characteristics in a prospective observational study of 339 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|